Human LRRK2 G2019S Rat

Random Transgenic

Human LRRK2 G2019S Random Transgenic Rat Model

NTac:SD Background

  • Model #
  • Genotype
  • Nomenclature
  • 10681-F
  • 10681-M
  • Line 10681 Rat carries the G2019S mutation on the human gene LRRK2. Hemizygotes are positive for the G2019S mutation.
  • The G2019S alpha-mutation is linked to the development of Parkinson's disease, both sporadic and familial.
  • Non-specific deterioration of the substantia nigra and absence of Lewy bodies is associated with the G2019S mutation.

Genetic Background:

NTac:SD Background


Line 10681 was developed in the laboratory of Chenjian Li at Cornell. The model was created through pronuclear injection of human gene LRRK2 with the G2019S mutation into NTac:SD zygotes. Founder line 571 was bred to NTac:SD. The colony is maintained by mating a wild type female with a hemizygous male to produce hemizygous pups. Taconic received stock from Cornell in 2010 and derived the rats through embryo transfer derivation.


Model Sponsor: The Michael J. Fox Foundation





Initial Publication:

Initial characterization of this model is in progress.

Terms of Use:
Nonprofit users may purchase rats off the shelf for research purposes under a simple label license (no signatures required). For-profit users must first execute a license agreement with Cornell University.

Conditions of Use for Parkinson's Disease Rat Models for Nonprofit Users:
The Parkinson's Disease Rat Models (Model), Taconic Models 10678, 10679, 10680, and 10681, are produced and distributed under rights to patents and/or intellectual property owned by Cornell University (Cornell). Taconic has rights to distribute the Model on behalf of Cornell. Cornell maintains ownership of the Model and permits the sale of such rats to each Buyer that agrees to the following Terms and Conditions of the Sale and following terms of use:

  • Title to the Model and biological materials derived from it remains with Cornell.
  • The Model will be used for research purposes only.
  • The Model may be bred, but may not be crossbred to another transgenic line or backcrossed to another strain background without the written consent of Cornell.
  • In publications of results with the Model, Recipient must cite Chenjian Li of Weill Cornell Medical College as creator of the Model.
  • The Model and biological materials derived from it will not be distributed to third parties (except to send tissues to a nonprofit collaborator or for fee-for-service staining or analysis work).
  • The Model and biological materials derived from it will not be used for commercial purposes.
  • Recipient may not use Model in research funded by a for-profit entity unless said for-profit has obtained a license for the Model from Cornell.
  • Recipient assumes all risk from using the Model and holds Cornell and its employees harmless.

For licensing information, contact:

Cornell Center for Technology Enterprise and Commercialization
Attention: Executive Director
395 Pine Tree Road, Suite 310
Ithaca, NY 14850

Fax: 607-254-5454
Phone: 607-254-5236
Cite: Docket D4184 (LRRK2) and D5203 (alpha-synuclein)